ArticleExperimental hematology & oncology2019

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma.

N O'Connor-Byrne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.